FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1654551777> ?p ?o ?g. }

• W1654551777 endingPage "6340" @default.
• W1654551777 startingPage "6326" @default.
• W1654551777 abstract "// Zhi-Jie Hou 1,* , Xi Luo 1,* , Wei Zhang 1,* , Fei Peng 1 , Bai Cui 1 , Si-Jin Wu 2 , Fei-Meng Zheng 1 , Jie Xu 1 , Ling-Zhi Xu 1 , Zi-Jie Long 3 , Xue-Ting Wang 1 , Guo-Hui Li 4 , Xian-Yao Wan 5 , Yong-Liang Yang 2 and Quentin Liu 1 1 Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China 2 Center for Molecular Medicine, School of Life Science and Biotechnology, Dalian University of Technology, Dalian, China 3 Department of Hematology, Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China 4 Laboratory of Molecular Modeling and Design, State Key Laboratory of Molecular Reaction Dynamics, Dalian Institute of Chemical Physics, The Chinese Academy of Sciences, Dalian, China 5 Department of Critical Care Medicine, the First Affiliated Hospital, Dalian Medical University, Dalian, China * These authors contributed equally to this work Correspondence to: Quentin Liu, email: // Yong-liang Yang, email: // Xian-Yao Wan, email: // Keywords : flubendazole, breast cancer, cancer stem-like cell, cell cycle, tubulin Received : August 23, 2014 Accepted : January 05, 2015 Published : January 21, 2015 Abstract Cancer stem-like cell (CS-like cell) is considered to be responsible for recurrence and drug resistance events in breast cancer, which makes it a potential target for novel cancer therapeutic strategy. The FDA approved flubendazole, has been widely used in the treatment of intestinal parasites. Here, we demonstrated a novel effect of flubendazole on breast CS-like cells. Flubendazole inhibited breast cancer cells proliferation in dose- and time-dependent manner and delayed tumor growth in xenograft models by intraperitoneal injection. Importantly, flubendazole reduced CD44 high /CD24 low subpopulation and suppressed the formation of mammosphere and the expression of self-renewal related genes including c-myc , oct4 , sox2, nanog and cyclinD1 . Moreover, we found that flubendazole induced cell differentiation and inhibited cell migration. Consistently, flubendazole reduced mesenchymal markers (β-catenin, N-cadherin and Vimentin) expression and induced epithelial and differentiation marker (Keratin 18) expression in breast cancer cells. Mechanism study revealed that flubendazole arrested cell cycle at G2/M phase and induced monopolar spindle formation through inhibiting tubulin polymerization. Furthermore, flubendazole enhanced cytotoxic activity of conventional therapeutic drugs fluorouracil and doxorubicin against breast cancer cells. In conclusion, our findings uncovered a remarkable effect of flubendazole on suppressing breast CS-like cells, indicating a novel utilization of flubendazole in breast cancer therapy." @default.
• W1654551777 created "2016-06-24" @default.
• W1654551777 creator A5004061274 @default.
• W1654551777 creator A5005403923 @default.
• W1654551777 creator A5013621439 @default.
• W1654551777 creator A5026079635 @default.
• W1654551777 creator A5047234646 @default.
• W1654551777 creator A5055356463 @default.
• W1654551777 creator A5056379313 @default.
• W1654551777 creator A5056728983 @default.
• W1654551777 creator A5059175082 @default.
• W1654551777 creator A5063914161 @default.
• W1654551777 creator A5075932970 @default.
• W1654551777 creator A5077565385 @default.
• W1654551777 creator A5079533477 @default.
• W1654551777 creator A5083967743 @default.
• W1654551777 creator A5089791792 @default.
• W1654551777 date "2015-01-21" @default.
• W1654551777 modified "2023-10-17" @default.
• W1654551777 title "Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells" @default.
• W1654551777 cites W1701849548 @default.
• W1654551777 cites W1909893903 @default.
• W1654551777 cites W1972941606 @default.
• W1654551777 cites W1979993490 @default.
• W1654551777 cites W1980325735 @default.
• W1654551777 cites W1981040474 @default.
• W1654551777 cites W1985339653 @default.
• W1654551777 cites W1992938097 @default.
• W1654551777 cites W2010412413 @default.
• W1654551777 cites W2014691022 @default.
• W1654551777 cites W2018151872 @default.
• W1654551777 cites W2021401668 @default.
• W1654551777 cites W2021757510 @default.
• W1654551777 cites W2023316892 @default.
• W1654551777 cites W2023427658 @default.
• W1654551777 cites W2024398462 @default.
• W1654551777 cites W2026967508 @default.
• W1654551777 cites W2029923597 @default.
• W1654551777 cites W2036044099 @default.
• W1654551777 cites W2038378870 @default.
• W1654551777 cites W2040854347 @default.
• W1654551777 cites W2041525960 @default.
• W1654551777 cites W2045456080 @default.
• W1654551777 cites W2071523786 @default.
• W1654551777 cites W2074347542 @default.
• W1654551777 cites W2078351146 @default.
• W1654551777 cites W2085134335 @default.
• W1654551777 cites W2091083659 @default.
• W1654551777 cites W2097906998 @default.
• W1654551777 cites W2099365945 @default.
• W1654551777 cites W2102746728 @default.
• W1654551777 cites W2106787323 @default.
• W1654551777 cites W2107023512 @default.
• W1654551777 cites W2119238594 @default.
• W1654551777 cites W2119337308 @default.
• W1654551777 cites W2125904252 @default.
• W1654551777 cites W2134959033 @default.
• W1654551777 cites W2137383619 @default.
• W1654551777 cites W2138993111 @default.
• W1654551777 cites W2140737952 @default.
• W1654551777 cites W2142918918 @default.
• W1654551777 cites W2146197063 @default.
• W1654551777 cites W2154285890 @default.
• W1654551777 cites W2156556190 @default.
• W1654551777 cites W2159640574 @default.
• W1654551777 cites W2160594160 @default.
• W1654551777 cites W2163292580 @default.
• W1654551777 cites W2167960944 @default.
• W1654551777 cites W2170685293 @default.
• W1654551777 cites W2171998898 @default.
• W1654551777 cites W2208508501 @default.
• W1654551777 cites W2320744367 @default.
• W1654551777 cites W2887635189 @default.
• W1654551777 cites W2007340367 @default.
• W1654551777 doi "https://doi.org/10.18632/oncotarget.3436" @default.
• W1654551777 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4467440" @default.
• W1654551777 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25811972" @default.
• W1654551777 hasPublicationYear "2015" @default.
• W1654551777 type Work @default.
• W1654551777 sameAs 1654551777 @default.
• W1654551777 citedByCount "71" @default.
• W1654551777 countsByYear W16545517772015 @default.
• W1654551777 countsByYear W16545517772016 @default.
• W1654551777 countsByYear W16545517772017 @default.
• W1654551777 countsByYear W16545517772018 @default.
• W1654551777 countsByYear W16545517772019 @default.
• W1654551777 countsByYear W16545517772020 @default.
• W1654551777 countsByYear W16545517772021 @default.
• W1654551777 countsByYear W16545517772022 @default.
• W1654551777 countsByYear W16545517772023 @default.
• W1654551777 crossrefType "journal-article" @default.
• W1654551777 hasAuthorship W1654551777A5004061274 @default.
• W1654551777 hasAuthorship W1654551777A5005403923 @default.
• W1654551777 hasAuthorship W1654551777A5013621439 @default.
• W1654551777 hasAuthorship W1654551777A5026079635 @default.
• W1654551777 hasAuthorship W1654551777A5047234646 @default.
• W1654551777 hasAuthorship W1654551777A5055356463 @default.
• W1654551777 hasAuthorship W1654551777A5056379313 @default.

• next